The Association Between Antihypertensive Medication Nonadherence and Visit-to-Visit Variability of Blood Pressure: Findings From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial

Hypertension

Volumn 68, Issue 1, 2016, Pages 39-45

  Kronish, Ian M ^a   Lynch, Amy I ^b   Oparil, Suzanne ^b   Whittle, Jeff ^c   Davis, Barry R ^d   Simpson, Lara M ^d   Krousel Wood, Marie ^e   Cushman, William C ^f   Chang, Tara I ^g   Muntner, Paul ^a  

^a Department of Medicine   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c CLEMENT J ZABLOCKI VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^e TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

blood pressure; cardiovascular disease; hypertension; medication adherence; prognosis

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; CHLORTALIDONE; DOXAZOSIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTILIPEMIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE VARIABILITY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT REFUSAL; VISIT TO VISIT VARIABILITY; AMBULATORY CARE; BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; ELECTROCARDIOGRAPHY; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT SELECTION; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE DETERMINATION; CALCIUM CHANNEL BLOCKERS; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; HYPOLIPIDEMIC AGENTS; LINEAR MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MYOCARDIAL INFARCTION; OFFICE VISITS; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84970044587     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.115.06960     Document Type: Article

References (28)

1. Muntner P, Whittle J, Lynch AI, Colantonio LD, Simpson LM, Einhorn PT, Levitan EB, Whelton PK, Cushman WC, Louis GT, Davis BR, Oparil S. Visit-to-visit variability of blood pressure and coronary heart disease, stroke, heart failure, and mortality: a cohort study. Ann Intern Med. 2015;163:329-338. doi: 10.7326/M14-2803.
2. Muntner P, Shimbo D, Tonelli M, Reynolds K, Arnett DK, Oparil S. The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994. Hypertension. 2011;57:160-166. doi: 10.1161/HYPERTENSIONAHA.110.162255.
3. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlöf B, Sever PS, Poulter NR. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010;375:895-905. doi: 10.1016/S0140-6736(10)60308-X.
4. Shimbo D, Newman JD, Aragaki AK, La Monte MJ, Bavry AA, Allison M, Manson JE, Wassertheil-Smoller S. Association between annual visit-to-visit blood pressure variability and stroke in postmenopausal women: data from the Women's Health Initiative. Hypertension. 2012;60:625-630. doi: 10.1161/HYPERTENSIONAHA.112.193094.
5. Diaz KM, Tanner RM, Falzon L, Levitan EB, Reynolds K, Shimbo D, Muntner P. Visit-to-visit variability of blood pressure and cardiovascular disease and all-cause mortality: a systematic review and meta-analysis. Hypertension. 2014;64:965-982. doi: 10.1161/HYPERTENSIONAHA.114.03903.
6. Rothwell PM. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet. 2010;375:938-948. doi: 10.1016/S0140-6736(10)60309-1.
7. Mazzaglia G, Ambrosioni E, Alacqua M, Filippi A, Sessa E, Immordino V, Borghi C, Brignoli O, Caputi AP, Cricelli C, Mantovani LG. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009;120:1598-1605. doi: 10.1161/CIRCULATIONAHA.108.830299.
8. Bailey JE, Wan JY, Tang J, Ghani MA, Cushman WC. Antihypertensive medication adherence, ambulatory visits, and risk of stroke and death. J Gen Intern Med. 2010;25:495-503. doi: 10.1007/s11606-009-1240-1.
9. Muntner P, Levitan EB, Lynch AI, Simpson LM, Whittle J, Davis BR, Kostis JB, Whelton PK, Oparil S. Effect of chlorthalidone, amlodipine, and lisinopril on visit-to-visit variability of blood pressure: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J Clin Hypertens (Greenwich). 2014;16:323-330. doi: 10.1111/jch.12290.
10. Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensivedrug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet. 2010;375:906-915. doi: 10.1016/S0140-6736(10)60235-8.
11. Osterberg LG, Urquhart J, Blaschke TF. Understanding forgiveness: minding and mining the gaps between pharmacokinetics and therapeutics. Clin Pharmacol Ther. 2010;88:457-459. doi: 10.1038/clpt.2010.171.
12. Davis BR, Cutler JA, Gordon DJ, et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. Am J Hypertens. 1996;9(4 pt 1):342-360.
13. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
14. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2000;283:1967-1975.
15. Levitan EB, Kaciroti N, Oparil S, Julius S, Muntner P. Relationships between metrics of visit-to-visit variability of blood pressure. J Hum Hypertens. 2013;27:589-593. doi: 10.1038/jhh.2013.19.
16. Lusk CM, Bettencourt J, Carroll L, Egan D, Ford CE, Kingry C, Johnason J, Sullivan S, Nwachuku C, Probstfield JL. The ALLHAT Adherence Survival Kit. Applied Clinical Trials. 2004;13:40-48.
17. Mena L, Pintos S, Queipo NV, Aizpúrua JA, Maestre G, Sulbarán T. A reliable index for the prognostic significance of blood pressure variability. J Hypertens. 2005;23:505-511.
18. Mackinnon DP. Introduction to Statistical Mediation Analysis. New York: Taylor and Francis; 2008.
19. Muntner P, Levitan EB, Joyce C, Holt E, Mann D, Oparil S, Krousel-Wood M. Association between antihypertensive medication adherence and visit-to-visit variability of blood pressure. J Clin Hypertens (Greenwich). 2013;15:112-117. doi: 10.1111/jch.12037.
20. Hong K, Muntner P, Kronish I, Shilane D, Chang TI. Medication adherence and visit-to-visit variability of systolic blood pressure in African Americans with chronic kidney disease in the AASK trial. J Hum Hypertens. 2016;30:73-78. doi: 10.1038/jhh.2015.26.
21. Hussein WF, Chang TI. Visit-to-visit variability of systolic blood pressure and cardiovascular disease. Curr Hypertens Rep. 2015;17:14. doi: 10.1007/s11906-014-0527-8.
22. Diaz KM, Veerabhadrappa P, Kashem MA, Feairheller DL, Sturgeon KM, Williamson ST, Crabbe DL, Brown MD. Relationship of visit-to-visit and ambulatory blood pressure variability to vascular function in African Americans. Hypertens Res. 2012;35:55-61. doi: 10.1038/hr.2011.135.
23. Gallagher BD, Muntner P, Moise N, Lin JJ, Kronish IM. Are two commonly used self-report questionnaires useful for identifying antihypertensive medication nonadherence? J Hypertens. 2015;33:1108-1113. doi: 10.1097/HJH.0000000000000503.
24. Shi L, Liu J, Koleva Y, Fonseca V, Kalsekar A, Pawaskar M. Concordance of adherence measurement using self-reported adherence questionnaires and medication monitoring devices. Pharmacoeconomics. 2010;28:1097-1107. doi: 10.2165/11537400-000000000-00000.
25. Tomaszewski M, White C, Patel P, Masca N, Damani R, Hepworth J, Samani NJ, Gupta P, Madira W, Stanley A, Williams B. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart. 2014;100:855-861. doi: 10.1136/heartjnl-2013-305063.
26. Stirratt MJ, Dunbar-Jacob J, Crane HM, Simoni JM, Czajkowski S, Hilliard ME, Aikens JE, Hunter CM, Velligan DI, Huntley K, Ogedegbe G, Rand CS, Schron E, Nilsen WJ. Self-report measures of medication adherence behavior: recommendations on optimal use. Transl Behav Med. 2015;5:470-482. doi: 10.1007/s13142-015-0315-2.
27. Smith TR, Drozda JP Jr, Vanslette JA, Hoeffken AS, Nicholson RA. Medication class effects on visit-to-visit variability of blood pressure measurements: analysis of electronic health record data in the "real world". J Clin Hypertens (Greenwich). 2013;15:655-662. doi: 10.1111/jch.12165.
28. Mancia G, Facchetti R, Parati G, Zanchetti A. Visit-to-visit blood pressure variability in the European Lacidipine Study on Atherosclerosis: methodological aspects and effects of antihypertensive treatment. J Hypertens. 2012;30:1241-1251. doi: 10.1097/HJH.0b013e32835339ac.